International Flavors (IFF) Down 14.1% Since Last Earnings Report: Can It Rebound?

Core Viewpoint - International Flavors (IFF) has experienced a decline in share price of approximately 14.1% since its last earnings report, underperforming the S&P 500 index [1][2]. Recent Earnings Report - In Q4 2025, IFF reported adjusted earnings of $0.80 per share, missing the Zacks Consensus Estimate of $0.85, and down from $0.93 in the same quarter last year [3]. - The company’s net sales for the quarter were $2.59 billion, a decrease of 6.6% year-over-year, but exceeded the Zacks Consensus Estimate of $2.51 billion [4]. - Currency-neutral sales increased by 1%, driven by mid-single-digit growth in Health & Biosciences and Scent, and low-single-digit growth in Taste [4]. Financial Metrics - Gross profit fell by 9.1% to $891 million, with a gross margin of 34.4%, down from 35.4% in the previous year [5]. - Research and development expenses rose by 2.4% to $174 million, while selling and administrative expenses increased by 12.8% to $383 million [6]. - Adjusted operating EBITDA was $437 million, a decrease of 7.2% from the prior year, with an adjusted operating EBITDA margin of 16.9% [6]. Segment Performance - The Taste segment saw net sales increase by 2.1% to $588 million, with adjusted operating EBITDA rising by 8% to $94 million [7]. - The Food Ingredients segment experienced a decline in net sales by 2.1% to $802 million, but adjusted operating EBITDA increased by 18% to $82 million [7]. - Health & Bioscience segment sales were $586 million, up from $555 million year-over-year, with adjusted operating EBITDA increasing by 14% to $155 million [8]. - The Scent segment's sales rose by 5.5% to $610 million, with adjusted operating EBITDA remaining flat at $106 million [8]. Cash Flow and Balance Sheet - At the end of 2025, IFF had cash and cash equivalents of $590 million, an increase from $469 million at the end of 2024 [9]. - Long-term debt decreased to $4.74 billion from $7.56 billion year-over-year [9]. - Cash generated from operating activities was $0.85 billion, down from $1.07 billion in the previous year [9]. 2025 Performance Overview - For the full year 2025, IFF reported adjusted earnings of $4.20 per share, missing the Zacks Consensus Estimate of $4.28, and down from $4.22 in 2024 [11]. - Total net sales for 2025 were $10.89 billion, a decrease of 5.2% year-over-year, but above the Zacks Consensus Estimate of $10.82 billion [12]. - Currency-neutral sales increased by 2%, attributed to volume growth, productivity gains, and favorable net pricing [12]. 2026 Guidance - IFF expects sales for fiscal 2026 to be between $10.5 billion and $10.8 billion, with adjusted EBITDA projected between $2.05 billion and $2.15 billion [13]. Estimate Trends - There has been a downward trend in estimates, with the consensus estimate decreasing by 7.58% recently [14]. VGM Scores - IFF currently holds a subpar Growth Score of D, a Momentum Score of B, and a Value Score of B, resulting in an aggregate VGM Score of C [15]. Industry Context - IFF operates within the Zacks Chemical - Specialty industry, where competitor Linde (LIN) has seen a 3.7% increase in share price over the past month [17].